{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:28Z","timestamp":1793293888032,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.09.020","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T23:13:22Z","timestamp":1608592402000},"page":"72-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Antisynthetase syndrome \u2013 much more than just a myopathy"],"prefix":"10.1016","volume":"51","author":[{"given":"Aleksandra Halina","family":"Opinc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Samanta","family":"Makowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.09.020_bib0001","first-page":"663","article-title":"Antibody to Jo-1 in polymyositis\/dermatomyositis: association with interstitial pulmonary disease","volume":"11","author":"Hochberg","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0002","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Qjm"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0003","series-title":"Antisynthetase syndrome","year":"2014"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-04979-8","article-title":"Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome","author":"Zhang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0005","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0006","first-page":"999","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0007","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0009","doi-asserted-by":"crossref","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08916930600622645","article-title":"Clinical implications of autoantibody screening in patients with autoimmune myositis","volume":"39","author":"Ghirardello","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0011","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/0002-9343(84)90677-6","article-title":"Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype","volume":"76","author":"Wasicek","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0012","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/BOR.0000000000000548","article-title":"New insights in myositis-specific autoantibodies","volume":"30","author":"Ghirardello","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0014","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.1780390424","article-title":"Coexistence of two antisynthetases in a patient with the antisynthetase syndrome","volume":"39","author":"Gelp\u00ed","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0016","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/128_2013_476","article-title":"Extracellular activities of aminoacyl-tRNA synthetases: new mediators for cell-cell communication","volume":"344","author":"Son","year":"2014","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0018","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0019","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11926-003-0052-2","article-title":"The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses","volume":"5","author":"Ascherman","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Zack Howard","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.30113","article-title":"Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis","volume":"63","author":"Soejima","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0022","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0023","doi-asserted-by":"crossref","first-page":"19269","DOI":"10.1074\/jbc.C114.571026","article-title":"Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis","volume":"289","author":"Zhou","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0024","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0025","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/art.22790","article-title":"Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis","volume":"56","author":"Levine","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0026","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.41075","article-title":"Proinflammatory histidyl\u2013transfer RNA synthetase\u2013specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies","volume":"72","author":"Galindo-Feria","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0027","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s10067-014-2567-5","article-title":"Environmental exposure in inflammatory myositis","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10067-013-2467-0","article-title":"Occupational exposure in patients with the antisynthetase syndrome","volume":"33","author":"Labirua-Iturburu","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0029","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","article-title":"Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study","volume":"71","author":"Chinoy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0030","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/annrheumdis-2017-211174","article-title":"Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study","volume":"76","author":"Svensson","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0031","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/art.40503","article-title":"Exacerbation of murine experimental autoimmune myositis by toll-like receptor 7\/8","volume":"70","author":"Sciorati","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0032","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.4049\/jimmunol.1501902","article-title":"Involvement of NK cells and NKp30 pathway in antisynthetase syndrome","volume":"197","author":"Hervier","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0033","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cei.12319","article-title":"Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications","volume":"177","author":"Zhang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0034","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups","volume":"78","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0036","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/BOR.0000000000000328","article-title":"New developments in genetics of myositis","volume":"28","author":"Rothwell","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0037","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","article-title":"Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type","volume":"108","author":"Johnson","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0038","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0039","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0041","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0042","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/annrheumdis-2019-215031","article-title":"Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria","volume":"78","author":"Greco","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0043","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5114\/reum.2020.93505","article-title":"The clinical phenotype associated with antisynthetase autoantibodies","volume":"58","author":"Masiak","year":"2020","journal-title":"Reumatologia"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0044","article-title":"Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Med (United States)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0045","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0046","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3899\/jrheum.171314","article-title":"Rheumatological assessment is important for interstitial lung disease diagnosis","volume":"45","author":"Levi","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00209","article-title":"Interstitial pneumonia with autoimmune features (IPAF)","volume":"6","author":"Fernandes","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0048","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0049","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6416378","article-title":"Effect of genetic and laboratory findings on clinical course of antisynthetase syndrome in a hungarian cohort","volume":"2018","author":"Szab\u00f3","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0051","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-jo1-positive patients with Anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0052","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0053","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0054","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.annder.2018.11.010","article-title":"Mechanics hands in patients with antisynthetase syndrome: 25 cases","volume":"146","author":"Gusdorf","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0055","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.rhum.2013.07.004","article-title":"Antisynthethase syndrome presenting as peripheral limb fasciitis","volume":"80","author":"Ebbo","year":"2013","journal-title":"Rev Du Rhum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0056","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1219-y","article-title":"Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study","volume":"19","author":"Andersson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0057","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0058","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0059","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000523","article-title":"In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome","volume":"94","author":"Meyer","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0060","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217624","article-title":"Antisynthetase syndrome (ASS) presenting as acute respiratory distress syndrome (ARDS) in a patient without myositis features","volume":"2016","author":"Kanchustambham","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0061","first-page":"76","article-title":"Acute respiratory failure as the first manifestation of antisynthetase syndrome","volume":"16","author":"Toujani","year":"2017","journal-title":"Tanaffos"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0062","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4046\/trd.2016.79.3.188","article-title":"Acute respiratory distress syndrome as the initial clinical manifestation of an Antisynthetase syndrome","volume":"79","author":"Kim","year":"2016","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0063","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0609-5","article-title":"Elevated \u03b1-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease","volume":"18","author":"Sakamoto","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0064","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0065","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jclinpath-2014-202367","article-title":"Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy","volume":"67","author":"Schneider","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0066","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0067","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0068","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0069","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0000000000000434","article-title":"Clinical spectrum of anti-Jo-1-associated disease","volume":"29","author":"Monti","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-016-8528-9","article-title":"Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS collaborative group","volume":"52","author":"Cavagna","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0071","first-page":"927","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lef\u00e8vre","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0072","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jbspin.2012.04.004","article-title":"Calcinosis and antisynthetase syndrome","volume":"79","author":"Zenone","year":"2012","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0073","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/rheumatology\/kep065","article-title":"Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy","volume":"48","author":"Labrador-Horrillo","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2018-000661","article-title":"Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy","volume":"4","author":"Ide","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0075","first-page":"44","article-title":"Timing of onset affects arthritis presentation pattern in antisynthetase syndrome","volume":"36","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0076","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00408-014-9665-7","article-title":"Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies","volume":"193","author":"Tomonaga","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0077","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.180355","article-title":"Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: results of a multicenter international study","volume":"46","author":"Sebastiani","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0078","first-page":"197","article-title":"18F-FDG PET\/CT in diagnosis and response evaluation in an unusual case of antisynthetase syndrome presenting as pyrexia of unknown origin","volume":"35","author":"Jain","year":"2016","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0079","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2133.2006.07593.x","article-title":"Mechanic's hands\u201d: a misleading cutaneous sign of the antisynthetase syndrome","volume":"156","author":"Bachmeyer","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0080","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-017-3598-5","article-title":"Hiker's feet\u201d: a novel cutaneous finding in the inflammatory myopathies","volume":"36","author":"Cox","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjoms.2013.07.003","article-title":"Facial calcinosis: case report","volume":"51","author":"Craggs","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0082","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mus.25507","article-title":"High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset","volume":"56","author":"Casal-Dominguez","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0083","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00739","article-title":"Dysphagia as isolated manifestation of JO-1 associated myositis","volume":"10","author":"Labeit","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0084","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bjoms.2013.12.006","article-title":"Antisynthetase syndrome: two cases presenting orofacial manifestations","volume":"52","author":"Gormley","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0003489417748331","article-title":"The voice of autoimmunity: antisynthetase syndrome manifesting as vocal fold bamboo nodes","volume":"127","author":"Kim","year":"2018","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0086","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3928\/23258160-20160901-13","article-title":"Retinal vasculitis in anti-synthetase syndrome","volume":"47","author":"Donovan","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0087","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226119","article-title":"Interstitial lung disease and inflammatory myopathy in antisynthetase syndrome with PL-12 antibody","volume":"2018","author":"Jubber","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0088","first-page":"763","article-title":"Scleroderma-like renal crisis in a patient with anti-threonyl-tRNA synthetase-associated antisynthetase syndrome","volume":"57","author":"Hermans","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0089","article-title":"Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies?","author":"Opinc","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cardfail.2014.07.012","article-title":"Brief report: antisynthetase syndrome-associated myocarditis","volume":"20","author":"Sharma","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0091","article-title":"Myocarditis in patients with antisynthetase syndrome: prevalence, presentation, and outcomes","volume":"94","author":"Dieval","year":"2015","journal-title":"Med (United States)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0092","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0093","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.110.010066","article-title":"Severe aortic regurgitation secondary to antisynthetase syndrome","volume":"124","author":"Ketlogetswe","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0094","first-page":"241","article-title":"High prevalence of metabolic syndrome in antisynthetase syndrome","volume":"36","author":"Araujo","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0096","doi-asserted-by":"crossref","DOI":"10.1186\/ar4332","article-title":"Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome","volume":"15","author":"Marie","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0097","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/RHU.0b013e31823b1878","article-title":"Antisynthetase syndrome and malignancy: our experience","volume":"17","author":"Casta\u00f1eda-Pomeda","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0098","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/RHU.0b013e3181b0e910","article-title":"Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience","volume":"15","author":"Mileti","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0099","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00296-017-3728-z","article-title":"Squamous cell carcinoma of the lung associated with anti-Jo1 antisynthetase syndrome: a case report and review of the literature","volume":"37","author":"Boleto","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.reuma.2012.07.002","article-title":"Sarcoma de Kaposi en paciente con s\u00edndrome antisintetasa en tratamiento corticoideo","volume":"9","author":"Bragado","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0101","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/RHU.0b013e31817d116f","article-title":"Malignancy in the setting of the anti-synthetase syndrome","volume":"14","author":"Rozelle","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0102","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0105","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","article-title":"Autoimmune myopathies: updates on evaluation and treatment","volume":"15","author":"McGrath","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0106","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00313897","article-title":"High single-dose alternate-day corticosteroid regimens in treatment of polymyositis","volume":"232","author":"Uchino","year":"1985","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0107","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0108","first-page":"858","article-title":"Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome","volume":"37","author":"Casal-Dominguez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3704","article-title":"Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine","volume":"14","author":"Schiopu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0110","first-page":"1050","article-title":"Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids","volume":"54","author":"Ibrahim","year":"2015","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0112","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0113","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"IC","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0114","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0115","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0116","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jca.21387","article-title":"Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease","volume":"30","author":"Omotoso","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0117","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jca.21285","article-title":"Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis","volume":"28","author":"Bozkirli","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0118","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0119","doi-asserted-by":"crossref","DOI":"10.1111\/j.1445-5994.2011.02702.x","article-title":"Efficacy of rituximab in refractory antisynthetase syndrome","volume":"42","author":"Limaye","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0120","first-page":"1420","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0121","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0122","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0123","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2007.07.010","article-title":"Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report","volume":"75","author":"Furlan","year":"2008","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jbspin.2015.03.016","article-title":"Antisynthetase syndrome treated with tocilizumab","volume":"83","author":"Beaumel","year":"2016","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0125","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0126","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0127","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Amato","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0130","first-page":"1307","article-title":"Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome","volume":"58","author":"Pinal-Fernandez","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0131","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0132","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type i interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0133","first-page":"2114","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0134","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0135","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0136","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0137","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/key123","article-title":"Bi-lung transplantation in anti-synthetase syndrome with life-threatening interstitial lung disease","volume":"57","author":"Delplanque","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.09.020_bib0138","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/joim.12481","article-title":"Physical exercise as a treatment for adult and juvenile myositis","volume":"280","author":"Alexanderson","year":"2016","journal-title":"J Intern Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220303085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220303085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:04:09Z","timestamp":1758733449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220303085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220303085"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.020","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisynthetase syndrome \u2013 much more than just a myopathy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}